-
MITSUBISHI TANABE PHARMA CORP. et al v. APOTEX, INC., et al DC
- 1:17-cv-05278
- D.N.J.
- Judge: Renee Marie Bumb +1
- Filed: 07/19/2017
- Closed: 07/23/2020
- Latest Docket Entry: 01/28/2021
- PACER
- Docket updated daily
5
Plaintiffs
2
Defendants
2
Accused
Products
2
Patents-in-Suit
1,101
Days in
Litigation
-
MITSUBISHI TANABE PHARMA CORP. et al v. APOTEX, INC., et al DC
- 1:17-cv-05278
- D.N.J.
- Judge: Renee Marie Bumb +1
- Filed: 07/19/2017
- Closed: 07/23/2020
- Latest Docket Entry: 01/28/2021
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Apotex Corporation
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic version of JPI’s INVOKAN 100 mgGeneric version of JPI’s INVOKAN 300 mgGeneric versions of 100 mg and 300 mg INVOKANA drug product | US 7,943,582 B2 | All Asserted Claims |
Willful infringement
Entry 16Entry 53 |
Generic version of JPI’s INVOKAN 100 mgGeneric version of JPI’s INVOKAN 300 mgGeneric versions of 100 mg and 300 mg INVOKANA drug product | US 8,513,202 B2 | All Asserted Claims |
Willful infringement
Entry 16Entry 53 |
Apotex Inc.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic version of JPI’s INVOKAN 100 mgGeneric version of JPI’s INVOKAN 300 mgGeneric versions of 100 mg and 300 mg INVOKANA drug product | US 7,943,582 B2 | All Asserted Claims |
Willful infringement
Entry 16Entry 53 |
Generic version of JPI’s INVOKAN 100 mgGeneric version of JPI’s INVOKAN 300 mgGeneric versions of 100 mg and 300 mg INVOKANA drug product | US 8,513,202 B2 | All Asserted Claims |
Willful infringement
Entry 16Entry 53 |
Hetero Labs Limited
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 13
|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Hetero Labs Limited Unit V
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 13
|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Hetero USA Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 13
|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 13
|
Laurus Labs Limited
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 17
|
Generic versions of 100 mg and 300 mg INVOKANA drug product | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 17
|
Lupin Limited
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Pharmaceutical products asserted to be bioequivalent to the Invokana, Invokamet, and Invokamet XR Products | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 19
|
Pharmaceutical products asserted to be bioequivalent to the Invokana, Invokamet, and Invokamet XR Products | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 19
|
Lupin Pharmaceuticals Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Pharmaceutical products asserted to be bioequivalent to the Invokana, Invokamet, and Invokamet XR Products | US 7,943,582 B2 | All Asserted Claims |
Infringement
Entry 19
|
Pharmaceutical products asserted to be bioequivalent to the Invokana, Invokamet, and Invokamet XR Products | US 8,513,202 B2 | All Asserted Claims |
Infringement
Entry 19
|